new member

2»

Comments

  • foxhd
    foxhd Member Posts: 3,181 Member
    #22
    KGField said:

    Votrient trial
    No, TW, I do not. My chances of not having a recurrence are moderate and I'm looking to up those odds.

    Let me clarify: this is a phase III double-blinded trial where GlaxoSmithKline is looking to establish that Votrient can be used as adjuvant therapy to prevent metastatic disease and/or increase disease-free survival. Patients need to have been diagnosed with localized clear cell RCC (or predominantly so), be 4-12 weeks post-nephrectomy, and be free of metastatic disease. 50% of the subjects will receive drug, 50% placebo.

    Refer to trial 113387 on the NCI website (http://cancer/gov).

    Please forgive me if I was unclear. The world of cancer survival is brand-spanking new to me.

    votrient
    By the way, welcome to our club. Pull up a chair and hang on. Lots of shared information here. I was encouraged to be part of this study. At Dana Farber. I opted out due to the time, travel and the fact that after I spent several hours at D-F, they never even called me back after I had their requested Pet scan. No follow up what so ever. ( I am now starting to believe that they KNEW I already had mets and didn't share this info with me or my local oncologist.) As you read more of our threads you'll see I entered a trial with MDX-1106. I feel very fortunate to be part of it. One surprise response I have recieved is from people who thank me for being part of a trial with such high expectations which may help others in the future. I have never felt like a lab rat but I guess I am. I guess you are too. Seems most people opt for standard treatments. Good luck in your recoveery. Fox.
  • Texas_wedge
    Texas_wedge Member Posts: 2,798
    #23
    KGField said:

    Votrient trial
    No, TW, I do not. My chances of not having a recurrence are moderate and I'm looking to up those odds.

    Let me clarify: this is a phase III double-blinded trial where GlaxoSmithKline is looking to establish that Votrient can be used as adjuvant therapy to prevent metastatic disease and/or increase disease-free survival. Patients need to have been diagnosed with localized clear cell RCC (or predominantly so), be 4-12 weeks post-nephrectomy, and be free of metastatic disease. 50% of the subjects will receive drug, 50% placebo.

    Refer to trial 113387 on the NCI website (http://cancer/gov).

    Please forgive me if I was unclear. The world of cancer survival is brand-spanking new to me.

    Votrient trial criteria
    Thanks for the clarification KG. This sphere may be new to you but you seem to be picking it up pdq!

    The inclusion criteria are a bit hypothetical, as Fox's post shows [fox, hound, lab rat - a shape-shifter it seems!] - 4-12 weeks post op. there can't be much certainty whether one has mets or not?

    As you'll quickly discover this is a fascinating Alice in Wonderland world. Trials that might show that you haven't acquired something that you perhaps wouldn't have got even without the drug and that, possibly, after receiving the placebo you have seemingly contracted something that you may have actually already had. It reminds a little of the Knight in crimson armour in Through the Looking Glass whose horse was successfully protected from shark bites by the special anklets it wore and who kept a mouse-trap on the horse's back.

    'I was wondering what the mouse-trap was for,' said Alice. 'It isn't very likely there would be any mice on the horse's back.'

    'Not very likely, perhaps,' said the Knight; 'but, if they do come, I don't choose to have them running all about.'

Discussion Boards